Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clot lysis phenotype and response to recombinant factor VIIa in plasma of haemophilia A inhibitor patients.

British journal of haematology - 1 Sept 2013

Bakhtiari Kamran, Kamphuisen Pieter W, Mancuso Maria E, Hamulyak Karly, Schutgens Roger E G, Santagostino Elena, Meijers Joost C M

Abstract excerpt

Recombinant activated factor VII (rFVIIa) is a haemostatic agent that is used for the treatment of haemophilia A patients with inhibitors. However, clinical response to rFVIIa is variable and unpredictable with currently available assays. We investigated the anti-fibrinolytic effects of rFVIIa in relation to thrombin generation (TG) and other haemostatic parameters in haemophilia A patients with inhibitors. After...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Coagulation Factor Inhibitors
Share to Factor VIIa

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Factor VIII

Share to Fibrin

Share to Fibrinolysis

Share to Hemophilia A

Share to Recombinant Proteins

Share to Thrombin

Source

Identifiers

PMID: 23889493
DOI: 10.1111/bjh.12470

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clot lysis phenotype and response to recombinant factor VIIa in plasma of haemophilia A inhibitor patients.PMID 23889493Read ↗

Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa.Semantic proximity Read ↗

The thrombin generation assay distinguishes inhibitor from non-inhibitor patients with severe haemophilia A.Semantic proximity Read ↗

Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin-independent impairment of the thrombin-activatable fibrinolysis inhibitor pathway.Semantic proximity Read ↗

Response of factor VIII and IX-deficient blood to wild type and high membrane affinity mutant factor VIIa in an in vitro whole blood clotting assay: possible correlation to clinical outcome.Semantic proximity Read ↗

A Novel Fibrinolysis Resistance Capacity Assay can Detect Fibrinolytic Phenotypes in Trauma Patients.Semantic proximity Read ↗

Bleeding phenotype of patients with moderate haemophilia A and B assessed by thromboelastometry and thrombin generation.Semantic proximity Read ↗

Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis.Semantic proximity Read ↗

Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A.Semantic proximity Read ↗

Coagulation activation-induced fibrinolysis biomarker changes depend on thrombophilic risk factors and their clinical phenotype: an interventional <i>in vivo</i> studySemantic proximity Read ↗

Variants of recombinant factor VIIa with increased intrinsic activity.Semantic proximity Read ↗

Prophylactic Therapy with Emicizumab in Patients with Hemophilia A: Benefits and ChallengesSemantic proximity Read ↗

Thrombin generation and bleeding in haemophilia A.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.